Join the Heart Failure Society of America for the First Virtual Annual Scientific Meeting

The Heart Failure Society of America Virtual Annual Scientific Meeting 2020, taking place September 30 – October 6, will feature more than 50 live, interactive scientific sessions, more than 400 abstracts, two Late-Breaking Clinical Trials sessions, unique opportunities to connect with colleagues, and much more.

With a full program offering the most continuing medical education (CME) credit hours ever offered at an HFSA Annual Scientific Meeting, HFSA2020 will bring attendees a virtual array with the best of science, research, and practical management ideal for all members of the interdisciplinary heart failure care team.

To make the virtual meeting more accessible to attendees within the United States and beyond, HFSA has reduced registration fees and timed the most critical sessions during convenient evening and weekend hours. HFSA members can attend the meeting for less than $100. Non-members can attend for $200 or less.

“A virtual meeting uniquely provides greater flexibility and accessibility for attendees. To carry those benefits forward, we have reduced our registration rates, focused our content on the most critical topics, and scheduled program sessions around the important work of our attendees,” said Biykem Bozkurt, MD, FHFSA, and President of the Heart Failure Society of America. “Session content will be available OnDemand immediately following live presentations, and stays available for up to 90 days. Ultimately, HFSA2020 attendees can access all the latest science and CME credits at times that work best for their schedules.”  

 

HFSA2020 will feature:

  • Two Late-Breaking Clinical Trials Sessions 
  • More than 50 interactive, multidisciplinary Scientific Sessions
  • Live chats with industry and ePoster presenters
  • Networking opportunities and lively discussions
  • A Virtual Exhibit Hall to showcase industry products along with product theaters

 

The HFSA2020 traditional opening plenary will be held on Saturday, October 3 - Healthcare Future 360° featuring:

  • Victor J. Dzau, MD, President, National Academy of Medicine (NAM)
  • Eugene Braunwald, MD, Chairman, TIMI Study Group, Professor Harvard Medical School, Brigham and Women's Hospital, Division of Cardiovascular Medicine
  • Harlan Krumholz, MD, SM, Yale School of Medicine, New Haven, CT
  • Nancy Brown, Chief Executive Officer, American Heart Association (AHA)
  • Jessica Mega, MD, MPH, Verily Life Sciences
  • George Mensah, MD, FACC, National Heart, Lung, and Blood Institute
  • Athena Poppas, MD, FACC, FASE, President, American College of Cardiology (ACC)

Find more information on HFSA Virtual ASM 2020 at https://hfsa.org/annualscientificmeeting or follow the meeting on social media using #HFSA2020. 

 

LATE-BREAKING CLINICAL TRIALS

Late-Breaking Clinical Trials Session 1: Saturday, October 3, 4:30 PM – 5:30 PM

  • Levosimendan Improves Hemodynamics And Submaximal Exercise Capacity In Ph-hfpef: Primary Results from the Help-ph-hfpef Multicenter Randomized Controlled Trial – Barry Borlaug, MD, Mayo Clinic
  • Mechanistic Insight Into the effect of Spironolactone for Preventing Heart Failure: Proteomics and Knowledge-Based Network Analysis from the Homage Trial – Joao Pedro Ferreira, MD, PhD, CIC-P de Nancy
  • Excess 30-Day Heart Failure Readmission In Blacks Increases with Neighborhood Deprivation – Shivani Patel, MPH, PhD, Emory University
  • Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) – John McMurray, MD, Institute of Cardiovascular and Medical Sciences
  • Kidney Function After Initiation and Discontinuation of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights from the Emperial Trials – Stefan Anker, MD, Charité University

 

Late-Breaking Clinical Trials Session 2: Monday October 5, 6:00 PM – 7:00 PM

  • Main Results of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients with Heart Failure Trial – Mikhail Kosiborod, MD, Saint Luke's Mid America Heart Institute
  • Effect of Vericiguat In Victoria According to Guideline-Directed Medical Therapy – Justin Ezekowitz, MD, CVC, University of Alberta
  • A Randomized Trial Comparing the Effect of Sacubitril/Valsartan to Valsartan On Left Ventricular Remodeling In Patients with Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction – Kieran Docherty, MBChB, Institute of Cardiovascular and Medical Sciences University of Glasgow
  • Endovascular Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction - First-in-Human Clinical Trial – Sanjiv Shah, MD, Northwestern University, Feinberg School of Medicine
  • Effect of Empagliflozin On Major Heart Failure Outcomes, Renal Function And Quality Of Life In Patients with Heart Failure with a Reduced Ejection Fraction, with and without Sacubitril/Valsartan – Milton Packer, MD, Baylor University Medical Center

 

About the Heart Failure Society of America

The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit www.hfsa.org.